Phase III study Cruise shows Lucentis improves vision in retinal vein occlusion patients (PharmaBiz)
July 31st, 2009
Genentech, Inc, a wholly-owned member of the Roche Group, announced that the phase-III study Cruise showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to central retinal vein occlusion.
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)